Daily BriefsSouth Korea

Daily Brief South Korea: Peptron, Lumir, Jeisys Medical, VIOL and more

In today’s briefing:

  • Peptron Rights Issue: The 25% Discount Is an Attractive Outright Position Opportunity
  • Lumir IPO Preview
  • Archimed Group Seeks Delisting of Jeisys Medical Through Stock Exchange
  • KOSDAQ150 Index Adhoc Rebalance Preview: Replacements for Jeisys Medical


Peptron Rights Issue: The 25% Discount Is an Attractive Outright Position Opportunity

By Sanghyun Park

  • Peptron’s lack of single-stock futures means no risk-free arbitrage but also less speculative selling, making the 25% discount an attractive outright position opportunity.
  • The low capital increase rate may stabilize the stock price, and more forfeited shares could lower the cost of securing subscription rights during the trading window.
  • Consider buying rights during the trading period or targeting forfeited shares. Conservatively estimate the final offering price range to set a profitable cost for securing rights.

Lumir IPO Preview

By Douglas Kim

  • Lumir is getting ready to complete its IPO on KOSDAQ in September. The IPO which is expected to raise between 49.5 billion won to 61.5 billion won.
  • Lumir specializes in the development of observation satellite technology including image data processing devices and onboard computers for a number of government satellite series.
  • Lumir had sales of 12.1 billion won (up 90.5% YoY) in 2023. Its sales surged by 477% YoY to reach 8.2 billion won in 1H24.

Archimed Group Seeks Delisting of Jeisys Medical Through Stock Exchange

By Douglas Kim

  • Jeisys Medical announced that it has decided to exchange shares with Syracus Subco, its largest shareholder. The stock exchange ratio between Syracus Subco and Jeisys Medical is 1 to 1.3575606. 
  • The exchange date is 23 October. Through this stock exchange, Archimed Group (owner of Syracus Subco) seeks to delist Jeisys Medical (287410 KS).
  • Jeisys Medical also announced that it plans to cancel 1,075,838 common shares, representing 1.4% of its outstanding shares. 

KOSDAQ150 Index Adhoc Rebalance Preview: Replacements for Jeisys Medical

By Brian Freitas


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars